UPEXI, INC.

Listed Company

UPXICIK 0001775194NasdaqEmerging GrowthFinance ServicesDelawareFY ends Jun 30

Period

FY 2025

Revenue

$15.81M

Net Income

$-13.68M

Total Assets

$123.81M

Equity

$90.10M

Shares Out

69.76M

Op. Cash Flow

$-8.42M

Business

Upexi, Inc. operates in the cryptocurrency sector while also serving as a consumer brand owner that develops, manufactures and distributes consumer products. Its principal services include managing a digital asset treasury concentrated in Solana (SOL) and staking activity, and producing consumer product lines such as LuckyTail pet care, PRAX energy, Cure Mushrooms, Moonwlkr cannabis-derived products, and gummies via Gumi Labs. The company’s key business areas comprise its SOL treasury and staking program, asset management and custody arrangements, brand manufacturing, and distribution subsidiaries. Upexi reaches customers through direct-to-consumer channels, wholesale partnerships, major third-party e-commerce platforms (including Amazon), and its own warehousing and fulfillment operations.

Summary from filing dated 2025-09-24

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Revenue	15	26	—	—	—
Digital asset revenue	985,009	0	—	—	—
Total revenue	16	26	36	23	24
Cost of revenue	5	13	15	8	12
Gross profit	11	13	21	15	12
Sales and marketing	4	6	6	5	2
Distribution costs	5	9	9	2	—
General and administrative expenses	12	7	7	9	6
Realized and unrealized (gain) loss on digital assets	−105,474	0	—	—	—
Share-based compensation	2	1	—	3	611,432
Amortization of acquired intangible assets	76,758	2	3	979,988	726,525
Depreciation	681,000	1	913,246	574,309	303,496
Impairment of long-lived asset - building	0	336,434	0	—	—
Loss on the sale / abandonment of assets in relocation	0	569,195	0	—	—
Impairment of intangible assets and goodwill	0	8	—	—	—
Lease impairment (gain on settlement), Delray Beach facility	−269,994	289,969	—	—	—
Operating expenses	23	35	33	21	10
Loss from operations	−12	−22	−12	−6	1
Other	−10,743	−16,443	−5	101,082	−269,396
Interest (expense) income, net	−1	−3	−5	−202,120	530,449
Other income (expense), net	−1	−3	—	—	—
Loss on operations before income tax	−14	−26	−17	−6	—
Income tax benefit (expense)	0	332,101	3	—	—
Total income tax expense benefit	0	332,101	3	518,398	1
Net loss from continuing operations	−14	−25	−14	−6	—
Interactive Offers	0	237,670	0	—	—
VitaMedica	0	2	0	—	—
E-core	0	−2	0	—	—
Gain (loss) from the sale of total	0	448,882	—	—	—
Infusionz	—	71,976	−338,418	—	—
Interactive Offers	0	−187,003	−2	—	—
VitaMedica	0	213,636	−382,449	—	—
E-core	0	1	1	—	—
Income (loss) income from discontinued operations	0	1	−1	−1	—
Net income (loss) attributable to Upexi, Inc.	−14	−24	—	−2	3
Income (loss) per share from continuing operations	−1.73	−24.6	−15.56	−0.36	—
(Loss) income per share from discontinued operations	0	1.13	−1.53	5	—
Total income (loss) per share attributable to Upexi shareholders	−1.73	−23.03	−18.94	−0.43	0.25
Income (loss) per share from continuing operations	−1.73	−24.6	−15.56	−0.07	—
(Loss) income per share from discontinued operations	0	1.13	−1.53	−0.36	—
Total income (loss) per share attributable to Upexi shareholders	−1.73	−23.03	−18.94	−0.43	0.21
Basic weighted average shares outstanding	8	1	893,943	16	12
Fully diluted weighted average shares outstanding	8	1	893,943	16	14

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Cash	3	661,415	4	7	—
Accounts receivable, net	157,515	606,885	1	939,875	1
Inventory, net	1	1	5	5	2
Due from VitaMedica transition	228,017	212,358	—	—	—
Prepaid expenses and other receivables	350,836	502,188	1	760,900	386,258
Current digital assets at fair value	50	0	—	—	—
Assets available for sale - Building	0	4	5	—	—
Purchase price receivable - VitaMedica	2	2	0	—	—
Purchase price receivable - E-core	0	2	0	—	—
Total current assets	57	11	30	17	18
Property and equipment, net	2	2	3	7	3
Intangible assets, net	163,113	239,871	7	9	2
Goodwill	848,854	848,854	3	5	2
Deferred tax asset	6	6	6	—	—
Digital assets at fair value, net of current	56	0	—	—	—
Other assets	192,123	278,435	76,728	75,613	49,068
Right-of-use asset, net	2	2	410,453	844,856	417,443
Total other assets	67	12	34	31	9
Total assets	124	24	64	48	27
Accounts payable	1	481,647	1	2	2
Accrued compensation	3	1	533,842	489,712	1
Deferred revenue	13,155	235,255	0	335,205	485,973
Accrued liabilities	356,064	736,407	2	816,632	296,021
Accrued interest	792,449	476,018	655,187	—	—
Acquisition payable	260,652	413,152	—	—	—
Related party advances, net	0	100,000	—	—	—
Current portion of note payable	560,000	0	338,474	749,752	447,100
Short-term treasury debt	20	0	—	—	—
Current portion of Cygnet subsidiary notes payable	5	5	795,778	—	—
Note payable on building for sale	0	3	—	—	—
Current portion of operating lease payable	691,010	1	454,127	183,881	199,532
Total current liabilities	33	13	22	10	6
Operating lease payable, net of current portion	1	2	0	700,411	217,430
Related party note payable	0	500,000	—	—	—
Note payable	0	557,429	5	—	—
Convertible notes payable	0	2	0	3	—
Total long-term liabilities	1	4	14	10	217,430
Preferred stock, $0.00001 par value, 10,000,000 shares authorized, and 150,000 and 25,000 shares issued and outstanding, respectively	2	1	25	500	500
Common stock, $0.00001 par value, 300,000,000 shares authorized, and 38,270,571 and 1,045,429 shares issued and outstanding, respectively	383	11	20,216	16,713	15,262
Additional paid in capital	151	53	52	35	25
Accumulated deficit	−61	−47	−23	−6	−4
Total stockholders' equity attributable to Upexi, Inc.	90	7	28	29	21
Total stockholders' equity	90	7	28	29	21
Total liabilities and stockholders' equity	124	24	64	48	27

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Net loss from operations	−14	−24	−17	−2	—
Depreciation and amortization	757,758	4	3	3	1
Unrealized (gain) loss on digital assets	−101,332	0	—	—	—
Gain on the sale of VitaMedica and income from discontinued operations	0	−2	0	—	—
Loss on the sale of New England Technology	0	2	0	—	—
Amortization of loan costs	30,462	115,787	—	—	—
Amortization of consideration discount	0	1	969,098	0	—
Inventory write-offs	748,874	2	118,990	1	375,000
Loss on sale of assets related to relocation of facility	0	569,195	—	—	—
Gain on sale of interactive offers	0	−237,670	0	—	—
Loss on the disposal of assets	10,743	0	—	—	—
Bad debt reserve for Amazon receivable	933,950	0	0	131,968	—
Reduction of acquisition payable	−152,500	0	—	—	—
Issuance of stock for services	250,000	0	0	576,774	—
Lease impairment (gain on settlement)	−269,994	0	—	—	—
Change in deferred tax asset	0	−344,802	—	—	—
Stock based compensation	2	1	—	3	611,432
Accounts receivable	−484,580	675,709	−364,665	284,998	−1
Inventory	−470,188	3	−1	−3	−846,659
Prepaid expenses and other assets	222,005	106,611	287,797	284,653	−313,206
Operating lease payable	20,965	302,050	4,238	37,922	—
Accounts payable and accrued liabilities	3	−944,020	389,458	−446,609	—
Deferred revenue	−222,100	101,305	0	−478,385	−99,770
Net cash provided by operating activities - Continuing Operations	−8	−5	−7	715,150	—
Net cash provided by (used in) operating activities - Discontinued Operations	0	5	8	−895,981	—
Net cash provided by operating activities	−8	−101,376	202,677	−180,831	3
Proceeds from the sale of the building, net	4	0	—	—	—
Proceeds from the sale of VitaMedica, Inc.	0	2	—	—	—
Proceeds from the sale of E-core	2	0	—	—	—
Proceeds from the sale of Interactive Offers, net of liabilities paid	0	203,025	0	—	—
Acquisition and sale of digital assets, net	−105	0	—	—	—
Acquisition of Cygnet Online LLC, net	0	−539,348	−500,000	−3	—
Acquisition of property and equipment	−387,760	−932,565	−937,564	−5	−1
Net cash provided by (used in) investing activities - Continuing Operations	−99	831,112	−23,271	−11	—
Net cash (used in) investing activities - Discontinued Operations	0	−4	−3	0	—
Net cash provided by (used in) investing activities	−99	−3	−3	−11	−1
Payment on acquisition notes payable	−66,655	−246,761	—	—	—
Payment on convertible note	−150,000	0	−6	0	—
Proceeds from issuance of short-term debt	20	0	—	—	—
Proceeds from warrant exercise	250,000	0	—	—	—
Proceeds from issuance of stock	93	0	—	0	11
Issuance of preferred stock series A	325,000	0	—	—	—
Repayment of related party advance	−175,000	0	—	0	−750,000
Proceeds from related party advance	75,000	100,000	0	0	—
Proceeds from issuance of convertible notes	350,000	0	3	—	—
Repayment of related party note payable	−500,000	0	−445,670	−1	−12,000
Repayment on note payable on building	−3	−207,028	—	—	—
Net cash used in financing activities - Continuing Operations	110	−353,789	6	4	—
Net cash (used in) provided by financing activities - Discontinued Operations	0	0	−6	0	—
Net cash used in financing activities	110	−353,789	−285,333	4	12
Net increase (decrease) in cash - Continuing Operations	2	−4	—	−7	14
Net (decrease) increase in cash - Discontinued Operations	0	586,551	—	—	—
Interest paid	805,880	839,000	2	64,460	—
Income tax paid	0	0	0	656,000	—
Issuance of common stock for acquisition of Cygnet	0	162,727	—	—	—
Non-cash proceeds in the sale of VitaMedica	0	2	—	—	—
Issuance of common stock for the repayment of convertible notes payable	2	500,000	0	—	—
Issuance of debt for acquisition of Cygnet	0	300,000	—	—	—
Bloomios non-cash payment of receivables, net	0	845,443	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro